Health Longevity Secrets
AI-Powered Longevity Science — One Gene to Reverse Aging? | Daniel Ives PhD
Why It Matters
The shift to AI‑driven, high‑throughput aging research dramatically accelerates discovery, turning years of wet‑lab work into virtual experiments that can be completed in months. This approach promises faster development of therapies that could extend healthspan and treat age‑related diseases, making the longevity revolution more tangible for investors, clinicians, and the public.
Key Takeaways
- •AI runs centuries of experiments in silico, accelerating discovery.
- •Mitochondrial DNA mutations alone don't drive epigenetic aging clocks.
- •Shift Bioscience uses single‑cell aging clocks to identify rejuvenation genes.
- •Partial Yamanaka reprogramming faces oncogenic risks, limited mechanisms.
- •Boosting mitochondrial number can slow epigenetic clock ticking.
Pulse Analysis
The episode highlights how AI and machine‑learning platforms now let researchers run centuries of wet‑lab experiments virtually, compressing discovery timelines dramatically. Dr. Daniel Ives explains that Shift Bioscience leverages single‑cell transcriptomics and high‑throughput aging clocks to screen thousands of genetic perturbations, then validates only the most promising hits in the lab.
\n\nIves recounts his early focus on mitochondrial DNA mutations as the root cause of aging, a theory that fell apart when epigenetic clocks—robust methylation‑based age biomarkers—showed no correlation with induced mitochondrial damage. Subsequent work revealed a broader link: increasing mitochondrial number or function can decelerate clock ticking, while disrupting membrane potential accelerates it.
\n\nFinally, the conversation contrasts classic partial reprogramming using Yamanaka factors with Shift’s approach of identifying single genes that rejuvenate cells without inducing pluripotency. While Yamanaka factors can reset epigenetic age, they carry oncogenic risk and obscure mechanistic insight. Shift’s AI‑driven screens have uncovered gene candidates that improve fibrosis and age‑related hearing loss, offering clearer translational pathways for investors and pharma partners seeking scalable, safety‑first longevity interventions.
Episode Description
What if an AI could run centuries of aging experiments in a year? Dr. Daniel Ives, CEO of Shift Bioscience, explains how his team used a virtual cell to discover SB000 — a single gene that matches Yamanaka factor rejuvenation without cancer risk.
CHAPTERS:
00:00 — Centuries of experiments in a year
02:03 — Daniel's journey: physics → Aubrey de Grey
10:08 — The epigenetic clock breakthrough
12:09 — The 13 mitochondrial genes
20:09 — Yamanaka factors (OSKM) explained
22:10 — Partial reprogramming: the weekend analogy
24:11 — The cancer risk problem
26:11 — AI virtual cell: how it works
32:12 — AI-driven dark labs
40:16 — Single-gene interventions
42:17 — Shift's discovery: genes that reverse aging
50:19 — Animal testing begins
62:20 — Hearing loss: the unexpected aging connection
66:21 — Rapamycin reverses hearing loss in animals
78:25 — N=1 medicine and wearables
84:26 — Closing
REFERENCES:
Shift Bioscience: shiftbioscience.com
Partial Reprogramming (Nature Comms, 2024): Nature
Epigenetic Clock (Frontiers in Aging, 2024): Frontiers
GUEST: Dr. Daniel Ives, PhD — CEO, Shift Bioscience, Cambridge UK
HOST: Dr. Robert Lufkin MD | robertlufkinmd.com
New episodes every Tuesday & Thursday. Subscribe so you don't miss one.
Continue this conversation on Substack: https://robertlufkinmd.substack.com
Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/
Web: https://www.robertlufkinmd.com
YouTube: https://www.youtube.com/robertlufkinmd
X: https://x.com/robertlufkinmd
Instagram: https://www.instagram.com/robertlufkinmd/
TikTok: https://www.tiktok.com/@robertlufkin
LinkedIn: https://www.linkedin.com/in/robertlufkinmd/
Comments
Want to join the conversation?
Loading comments...